Table 3.
Logistic regression analysis of hBD1, hBD2, hBD3 and hBD4 in serum of COVID-19 cases and controls.
hBD | Model I |
Model II |
Model III |
|||
---|---|---|---|---|---|---|
OR (95% CI)† | p (pc) | OR (95% CI)† | p (pc) | OR (95% CI)† | p (pc) | |
hBD1 | 1.004 (0.996–1.011) | 0.343 (1.0) | 1.004 (0.996–1.012) | 0.351 (1.0) | 1.005 (0.997–1.012) | 0.232 (0.928) |
hBD2 | 0.996 (0.993–.998) | 0.001 (0.004) | 0.996 (0.993–0.998) | 0.001 (0.004) | 0.996 (0.993–0.998) | 0.001 (0.004) |
hBD3 | 0.999 (0.997–1.000) | 0.037 (0.148) | 0.998 (0.997–1.000) | 0.028 (0.112) | 0.998 (0.997–1.000) | 0.031 (0.124) |
hBD4 | 4.781 (2.579–8.863) | < 0.001 (< 0.001) | 4.926 (2.627–9.239) | < 0.001 (< 0.001) | 4.948 (2.632–9.302) | < 0.001 (< 0.001) |
hBD: Human β-defensin; OR: Odds ratio; CI: Confidence interval; p: Probability; pc: Bonferroni-corrected probability; †: The reference category was controls, and the analysis was adjusted for age (Model I), age and gender (Model II), or age, gender and body mass index (Model III). Significant p-value is bold-marked.